MX2022013849A - Proteinas contra el cancer. - Google Patents

Proteinas contra el cancer.

Info

Publication number
MX2022013849A
MX2022013849A MX2022013849A MX2022013849A MX2022013849A MX 2022013849 A MX2022013849 A MX 2022013849A MX 2022013849 A MX2022013849 A MX 2022013849A MX 2022013849 A MX2022013849 A MX 2022013849A MX 2022013849 A MX2022013849 A MX 2022013849A
Authority
MX
Mexico
Prior art keywords
cancer proteins
cancer
recombinant lectin
treatment
subject
Prior art date
Application number
MX2022013849A
Other languages
English (en)
Inventor
Dhananjay Sathe
Sarvanakumar Iyappan
Dilip Pawar
Original Assignee
Unichem Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unichem Lab Ltd filed Critical Unichem Lab Ltd
Publication of MX2022013849A publication Critical patent/MX2022013849A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Una lectina recombinante para usar en un método de tratamiento del cáncer mediante la inhibición de la angiogénesis en un sujeto. El tratamiento comprende la administración de una cantidad terapéuticamente efectiva de la lectina recombinante.
MX2022013849A 2020-05-07 2021-04-28 Proteinas contra el cancer. MX2022013849A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202021019406 2020-05-07
PCT/IB2021/053503 WO2021224724A1 (en) 2020-05-07 2021-04-28 Anti-cancer proteins

Publications (1)

Publication Number Publication Date
MX2022013849A true MX2022013849A (es) 2023-01-16

Family

ID=75914557

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013849A MX2022013849A (es) 2020-05-07 2021-04-28 Proteinas contra el cancer.

Country Status (10)

Country Link
US (1) US20230348564A1 (es)
EP (1) EP4146243A1 (es)
JP (1) JP2023524151A (es)
KR (1) KR20230008072A (es)
CN (1) CN115515619A (es)
AU (1) AU2021267196A1 (es)
BR (1) BR112022022329A2 (es)
CA (1) CA3177876A1 (es)
MX (1) MX2022013849A (es)
WO (1) WO2021224724A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100486784B1 (ko) 2001-05-22 2005-04-29 김하형 솔비나무로 부터 추출된 렉틴 단백질, 그의 제조방법 및용도
KR20030028855A (ko) 2001-10-04 2003-04-11 (주)바이오메디팜 렉틴으로 강화된 겨우살이 추출물을 유효성분으로 하는항암제용 조성물
KR100492940B1 (ko) 2002-05-27 2005-06-02 김종배 항종양활성 증진용 조성물
TR201901202T4 (tr) 2009-02-18 2019-02-21 Karnatak Univ Antitümör aktivitesi olan rekombinant lektinlere bağlanan kanser hücresi ve hazirlama yöntemi.
WO2014203261A2 (en) 2010-02-02 2014-12-24 Unichem Laboratories Ltd. Recombinant lectin and method of preparing thereof
EP2508195A1 (de) 2011-04-06 2012-10-10 Cytavis BioPharma GmbH Arzneimittel enthaltend rekombinante Mistellektine zur Behandlung des malignen Melanoms
WO2015081290A1 (en) 2013-11-27 2015-06-04 Inis Biotech Llc Methods for modulating angiogenesis of cancers refractory to anti-vegf treatment
CN106397554A (zh) 2016-10-19 2017-02-15 上海市农业科学院 一种蛹虫草凝集素蛋白Lectin‑ccm3及其制备方法和应用
SG11202101391WA (en) 2018-08-31 2021-03-30 Unichem Lab Ltd Recombinant lectin variants
CA3112250A1 (en) * 2018-09-16 2020-04-16 Unichem Laboratories Ltd Protein for treatment of inflammatory diseases

Also Published As

Publication number Publication date
JP2023524151A (ja) 2023-06-08
US20230348564A1 (en) 2023-11-02
KR20230008072A (ko) 2023-01-13
EP4146243A1 (en) 2023-03-15
CA3177876A1 (en) 2021-11-11
AU2021267196A1 (en) 2023-01-05
BR112022022329A2 (pt) 2022-12-13
CN115515619A (zh) 2022-12-23
WO2021224724A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
PH12020500286A1 (en) Use of agonists of formly peptide receptor 2 for treating ocular inflammatory diseases
MX2019005400A (es) Variantes de il-2 para el tratamiento de enfermedades autoinmunes.
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
MX2021002764A (es) Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores.
MX2020008771A (es) Agonistas del estimulador de genes interferon.
EP3606964A4 (en) SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
MY186977A (en) Tetrasubstituted alkene compounds and their use
NZ766454A (en) Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent
EA202090510A1 (ru) Способ лечения бокового амиотрофического склероза придопидином
JOP20200268A1 (ar) تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
MD20160016A2 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
TW201613589A (en) Combination methods for treating cancers
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
MX2019009586A (es) Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal.
MX2022000143A (es) Metodos novedosos.
MX2020012611A (es) Composiciones liofilizadas de alta area de superficie que comprenden arsenico para administracion oral en pacientes.
JOP20210045A1 (ar) مترافقات جسم مضاد وعقار هربوكسيديين وطرق استخدامها
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2023008849A (es) Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico.
MX2021012872A (es) Polipeptidos multiespecificos terapeuticos activados mediante intercambio de cadenas polipeptidicas.
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MX2021001832A (es) Conjugados para su uso en metodos de tratamiento del cancer.
MX2022013849A (es) Proteinas contra el cancer.